|
Video: What is a Stock Split?
|
|
Celldex Therapeutics is a biopharmaceutical company focused on developing therapeutic monoclonal and bispecific antibodies. Co.'s clinical development programs include: CDX-0159, which is a human monoclonal antibody that specifically binds the receptor tyrosine kinase KIT; CDX-1140, which is a human monoclonal antibody targeted to CD40, a key activator of immune response, which is being studied in a Phase1 study; and CDX-527, which is a bispecific antibody that uses Co.'s proprietary anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway, for which Co. has initiated a Phase 1 study in advanced solid tumors. According to our CLDX split history records, Celldex Therapeutics has had 2 splits. | |
|
Celldex Therapeutics (CLDX) has 2 splits in our CLDX split history database. The first split for CLDX took place on March 10, 2007. CLDX's second split took place on February 11, 2019. This was a 1 for 15 reverse split, meaning for each 15 shares of CLDX owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 66.6666666666667 share position following the split.
When a company such as Celldex Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the CLDX split history from start to finish, an original position size of 1000 shares would have turned into 66.6666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Celldex Therapeutics shares, starting with a $10,000 purchase of CLDX, presented on a split-history-adjusted basis factoring in the complete CLDX split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/22/2014 |
|
End date: |
04/19/2024 |
|
Start price/share: |
$240.15 |
|
End price/share: |
$37.98 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-84.18% |
|
Average Annual Total Return: |
-16.84% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$1,581.78 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
03/10/2007 | 1 for 1 | 02/11/2019 | 1 for 15 |
|
|